145 related articles for article (PubMed ID: 21110238)
1. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents.
Pollock RF; Valentine WJ; Goodall G; Brändle M
Swiss Med Wkly; 2010; 140():w13103. PubMed ID: 21110238
[TBL] [Abstract][Full Text] [Related]
2. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
3. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
4. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
Tunis SL; Minshall ME
Am J Manag Care; 2008 Mar; 14(3):131-40. PubMed ID: 18333705
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France.
Alshannaq H; Pollock RF; Joubert M; Ahmed W; Norman GJ; Lynch PM; Roze S
J Comp Eff Res; 2024 Mar; 13(3):e230174. PubMed ID: 38294332
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting.
Brändle M; Goodall G; Erny-Albrecht KM; Erdmann E; Valentine WJ
Swiss Med Wkly; 2009 Mar; 139(11-12):173-84. PubMed ID: 19330561
[TBL] [Abstract][Full Text] [Related]
10. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study.
Davis WA; Bruce DG; Davis TM
Diabetes Care; 2006 Aug; 29(8):1764-70. PubMed ID: 16873777
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.
Chaugule S; Graham C
J Med Econ; 2017 Nov; 20(11):1128-1135. PubMed ID: 28745578
[TBL] [Abstract][Full Text] [Related]
12. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
[TBL] [Abstract][Full Text] [Related]
13. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
14. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.
Isitt JJ; Roze S; Tilden D; Arora N; Palmer AJ; Jones T; Rentoul D; Lynch P
Diabet Med; 2022 Jul; 39(7):e14831. PubMed ID: 35298036
[TBL] [Abstract][Full Text] [Related]
15. Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11).
Weber C; Schneider B; Lodwig V; Holm MV; Neeser K
Swiss Med Wkly; 2007 Oct; 137(39-40):545-50. PubMed ID: 17990145
[TBL] [Abstract][Full Text] [Related]
16. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K.
Roze S; Isitt J; Smith-Palmer J; Javanbakht M; Lynch P
Diabetes Care; 2020 Oct; 43(10):2411-2417. PubMed ID: 32647050
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type 2 diabetes in Canada.
Alshannaq H; Isitt JJ; Pollock RF; Norman GJ; Cogswell G; Lynch PM; Roze S
J Comp Eff Res; 2023 Oct; 12(10):e230075. PubMed ID: 37668608
[No Abstract] [Full Text] [Related]
18. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
19. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001.
Lecomte P; Romon I; Fosse S; Simon D; Fagot-Campagna A
Diabetes Metab; 2008 Jun; 34(3):219-26. PubMed ID: 18343703
[TBL] [Abstract][Full Text] [Related]
20. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
